A Phase 1 interventional study of 400mg progesterone Callavid - 2hr wear and Cyclogest 400 mg in Luteal Phase Insuffiency and Progesterone Delivery, sponsored by Calla Lily Clinical Care Ltd. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Calla Lily Clinical Care Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this clinical trial is to assess safety of a new vaginal 400mg progesterone drug-device combination product in a first in human trial. Additionally, it aims to assess user acceptability and ability to deliver progesterone. This Phase I trial is a randomised open-label first-in-human crossover trial, recruiting participants who are non-pregnant with luteal phase insufficiency. The main questions it aims to answer are:
This is the only study on the registry with Calla Lily Clinical Care Ltd as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are randomised to use Callavid first for 2 hour wear before crossing over to use Cyclogest. In the third round, participants receive Callavid again but for 3 hour wear.
Combination Product: 400mg progesterone Callavid - 2hr wear · Drug: Cyclogest 400 mg · Combination Product: 400mg progesterone Callavid - 3hr wear
Participants are randomised to use Cyclogest first before crossing over to use Callavid for 2 hour wear. In the third round, participants receive Callavid again but for 3 hour wear.
Combination Product: 400mg progesterone Callavid - 2hr wear · Drug: Cyclogest 400 mg · Combination Product: 400mg progesterone Callavid - 3hr wear
400mg progesterone Callavid, 2 hour wear, twice daily for 7 days
Cyclogest 400 mg pessary, twice daily for 7 days
400mg progesterone Callavid, 3 hour wear, twice daily for 7 days
Adverse events recorded from 400 mg progesterone Callavid
Any grade of adverse events, specifically allergy, gastrointestinal (bloating, constipation), neurological (headache, drowsiness, euphoria) according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From treatment up to 24 hours after the last dose
PROMIS Anxiety questionnaire
PROMIS short 4-item anxiety fear instrument
Time frame: Day 1 and day 7 of treatment in each round (3 rounds total)
Acceptability questionnaires
User acceptability questionnaires on 400mg progesterone Callavid
Time frame: Day 1 and day 7 of treatment in each round (3 rounds total)
Semi-structured user experience interviews
Semi-structured interviews with participants after completion of the crossover rounds.
Time frame: day 7
Delivery of vaginal progesterone into the blood at 2 hour and 3 hour wear
The serum progesterone levels at time 0, 3- and 6-hour after the first dose on day 1 and the thirteenth dose which is on day 7 each round of treatment are measured. Progesterone levels are measured for both 400 mg progesterone Callavid and 400 mg Cyclogest.
Time frame: Multiple time points on Day 1 and Day 7 of each treatment
Plan to share: Yes — Requests for anonymised participant data should be directed to the Sponsor at clinicaltrials@callali.ly. All requests will be considered by Institution Governance and a data sharing agreement might be required.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Utrogestan